Professor LUI Tak Wai, David

Prof David Lui

Clinical Assistant Professor

  • MBBS (Hons) (HK); MRCP (UK); FHKCP; FHKAM (Medicine)
Biography
Prof David Lui obtained his MBBS degree with Honours from the University of Hong Kong in 2012 and obtained his MRCP (UK) in 2015. He completed his specialty training in Endocrinology, Diabetes and Metabolism in 2019 and Advanced Internal Medicine in 2020 at the Queen Mary Hospital. He joined the Department of Medicine, the University of Hong Kong, as a Clinical Assistant Professor in March 2021.

Prof Lui’s research interests include diabetic bone disease, HDL function and diabetes, pharmacoepidemiology in type 2 diabetes and the interrelationship between COVID-19 and endocrinology. Supported by Health and Medical Research Fund, he is leading a randomized controlled trial on the effect of simvastatin on bone density among postmenopausal women with type 2 diabetes, and studying the epidemiological aspects of fractures in type 2 diabetes in Hong Kong. Using population-based datasets, he has published real-world evidence on the safety and efficacy of novel anti-diabetic agents (including SGLT2 inhibitors) from various perspectives. Amidst the COVID-19 pandemic, he has established cohorts of COVID-19 patients for the evaluation of endocrine dysfunction in the context of COVID-19 infection and vaccination.

He has published over 70 peer-reviewed articles in international journals including Diabetes Care, EClinicalMedicine, JAMA Network Open and PLoS Medicine. Two of his publications have been listed among the Essential Science Indicators (ESI) Highly Cited Papers. In recognition of his research work, he has been awarded both locally and internationally, including the Distinguished Research Paper Award for Young Investigators from the Hong Kong College of Physicians (2021, 2022 and 2023) and the Rising Star Award in the International Congress of Diabetes and Metabolism (2021).

Research Profile
  • Diabetic bone disease: epidemiology of fractures in type 2 diabetes; biomarkers in relation to bone health in type 2 diabetes
  • Lipidology: HDL function and diabetes
  • Pharmacoepidemiology of type 2 diabetes: focusing on novel anti-diabetic agents
  • COVID-19 (& vaccines) and endocrinology: focusing on thyroid and diabetes

Selected publications
  1. Lui DTW*, Tang EHM*, Au ICH, Wu T, Lee CH, Wong CK, Cheung CYY, Fong CHY, Chow WS, Woo YC, Tan KCB, Lam KSL, Wong CKH. Evaluation of fracture risk among type 2 diabetes patients with non-valvular atrial fibrillation receiving different oral anticoagulants. Diabetes Care. 2022 Nov 1;45(11):2620-2627. (2022 JIF: 16.2; 6/145 in Endocrinology & Metabolism; *co-first author)
  2. Lui DTW, Cheung CL, Lee ACH, Wong Y, Shiu SWM, Tan KCB. Carbamylated HDL and mortality outcomes in type 2 diabetes. Diabetes Care. 2021 Mar;44(3):804-809. (2022 JIF: 16.2; 6/145 in Endocrinology & Metabolism; first author)
  3. Xiong X*, Lui DTW*, Chung MSH, Au ICH, Lai FTT, Wan EYF, Chui CSL, Li X, Cheng FWT, Cheung CL, Chan EWY, Lee CH, Woo YC, Tan KCB, Wong CKH, Wong ICK. Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: a population-based cohort study. PLoS Med. 2023 Jul 24;20(7):e1004274. (2022 JIF 15.8; 12/167 in Medicine, General & Internal; *co-first author)
  4. Lui DTW*, Au ICH*, Tang EHM, Cheung CL, Lee CH, Woo YC, Wu T, Tan KCB, Wong CKH. Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: a real-world population-based analysis. EClinicalMedicine. 2022 Jun 25;50:101510. doi: 10.1016/j.eclinm.2022.101510. (2022 JIF: 15.1; 13/167 in Medicine, General & Internal; *co-first author)
  5. Lui DTW*, Chung MSH*, Lau EHY, Lau KTK, Au ICH, Lee CH, Woo YC, Wong CKH, Cowling BJ. Analysis of all-cause hospitalization and death among non-hospitalized patients with type 2 diabetes and SARS-CoV-2 infection treated with molnupiravir and nirmatrelvir-ritonavir during the Omicron wave in Hong Kong. JAMA Netw Open. 2023 May 1;6(5):e2314393. (2022 JIF 13.8; 15/167 in Medicine, General & Internal; *co-first author)
  6. Wong CKH*, Lui DTW*, Xiong X*, Chui CSL, Lai FTT, Li X, Wan EYF, Cheung CL, Lee CH, Woo YC, Au ICH, Chung MSH, Cheng FWT, Tan KCB, Wong ICK. Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients. BMC Med. 2022 Oct 14;20(1):339. (2022 JIF: 9.3; 16/167 in Medicine, General & Internal; *co-first author)
  7. Lui DTW*, Tang EHM*, Wu T, Au ICH, Lee CH, Woo YC, Tan KCB, Wong CKH. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based study in Hong Kong. Cardiovascular Diabetology. 2023 Feb 24;22(1):40. (2022 JIF: 9.3; 10/145 in Endocrinology & Metabolism; *co-first author)
  8. Wong CKH, Lau KTK, Tang EHM, Lee CH, Lee CYY, Woo YC, Tan KCB, Lui DTW. Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study. Cardiovascular Diabetology. 2022 Jun 3;21(1):92. (2022 JIF: 9.3; 10/145 in Endocrinology & Metabolism; corresponding author)
  9. Lui DTW, Lee CH, Woo YC, Fong CHY, Tso AWK, Cheung BMY, Lam TH, Janus E, Lam KSL. Cohort Profile: The Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS) and the follow-up studies. Int J Epidemiol. 2021 Aug 30;50(4):1069-1069h. (2022 JIF: 7.7; 19/207 in Public, Environmental & Occupational Health; first author)
  10. Wong CKH*, Lui DTW*, Lui AYC*, Kwok ACY, Low MCH, Lau KTK, Au ICH, Xiong X, Chung MSH, Lau EHY, Cowling BJ. Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: propensity score analysis of a territory-wide cohort in Hong Kong. Diabetes Metab. 2022 Jan;48(1):101307. (2022 JIF: 7.2; 22/145 in Endocrinology & Metabolism; *co-first author)
  11. Xiong X, Wong CKH, Au ICH, Lai FTT, Li X, Wan EYF, Chui CSL, Chan EWY, Cheng FWT, Lau KTK, Lee CH, Woo YC, Lui DTW*, Wong ICK*. Safety of inactivated and mRNA COVID-19 vaccination among patients treated for hypothyroidism: a population-based cohort study. Thyroid. 2022 May;32(5):505-514. (2022 JIF 6.6; 24/145 in Endocrinology & Metabolism; *co-corresponding author) (ESI Highly Cited Paper; Thyroid® The Top-Read Articles of 2022)
  12. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, Law CY, Leung EKH, To KKW, Tan KCB, Woo YC, Lam CW, Hung IFN, Lam KSL. Thyroid Dysfunction in Relation to Immune Profile, Disease Status and Outcome in 191 Patients with COVID-19. J Clin Endocrinol Metab. 2021 Jan 23;106(2):e926-e935. (2022 JIF: 5.8; 31/145 in Endocrinology & Metabolism; first author) (ESI Highly Cited Paper; JCEM Highly Cited Articles 2019-2021; top 10% of articles published in JCEM in 2020-2021 & 2021-2022)
  13. Lui DTW, Lee CH, Cheung CYY, Mak JHC, Fong CHY, Lui BWC, Cheung VSY, Chow WS, Lee ACH, Tam AR, Pang P, Ho TY, Tan KCB, Woo YC, Hung IFN, Lam KSL. Effect of COVID-19 vaccines on thyroid function and autoimmunity and effect of thyroid autoimmunity on antibody response. J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3781-e3789. (2022 JIF: 5.8; 31/145 in Endocrinology & Metabolism; first and corresponding author) (Top 10% of articles published in JCEM in 2021-2022)
  14. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, Law CY, Leung EKH, To KKW, Tan KCB, Woo YC, Lam CW, Hung IFN, Lam KSL. Insights from prospective follow-up of thyroid function and autoimmunity among COVID-19 survivors. Endocrinol Metab (Seoul). 2021 Jun;36(3):582-589. (2022 JIF: 3.4; 84/145 in Endocrinology & Metabolism; first author) (Top-cited paper in EnM 2021-2022 in the field of thyroid)
  15. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, Law CY, Leung EKH, To KKW, Tan KCB, Woo YC, Lam CW, Hung IFN, Lam KSL. Role of non-thyroidal illness syndrome in predicting adverse outcomes in COVID-19 patients predominantly of mild to moderate severity. Clin Endocrinol (Oxf). 2021 Sep;95(3):469-477. (2022 JIF: 3.2; 89/145 in Endocrinology & Metabolism; first author) (Top Cited Article 2020-2021 & 2021-2022 in Clinical Endocrinology)
  16. Lui DTW, Lee ACH, Tan KCB. Management of familial hypercholesterolemia: current status and future perspectives. J Endocr Soc. 2020 Aug 21;5(1):bvaa122. (first author) (Endocrine Society Thematic Issue on Lipids and Adipocytes 2021; top 10% of articles published in JES in 2021-2022)




Awards
  • Distinguished Research Paper Award for Young Investigators, Hong Kong College of Physicians (2023)
  • Merit Abstract Award in Clinical Research, 28th Medical Research Conference (2023)
  • Li Ka Shing Medical Fellowship for Internal Medicine (2023)
  • Faculty Outstanding Research Output Award, HKUMed (2022)
  • Distinguished Research Paper Award for Young Investigators, Hong Kong College of Physicians (2022) (with Best Presenter Award)
  • ISE Abstract Award, 20th International Congress of Endocrinology (2022)
  • Endocrine Society Outstanding Abstract Award, ENDO 2022 (2022)
  • Best Abstract in Clinical Medicine (Poster), 27th Medical Research Conference (2022)
  • Best Poster Exhibition Award in 9th Seoul International Congress of Endocrinology and Metabolism (2021)
  • Rising Star Award, International Congress of Diabetes and Metabolism (2021)
  • Distinguished Research Paper Award for Young Investigators, Hong Kong College of Physicians (2021)
  • Best Abstract in Clinical Medicine (Oral), 26th Medical Research Conference (2021)
  • International Non-Fellow Physician AACE Travel Grant Award, AACE 29th Annual Scientific & Clinical Congress (2020)
  • Poster Award, Asia Islet Biology & Incretin Symposium (2019)
  • Best Abstract in Clinical Medicine (Poster), 24th Medical Research Conference (2019)


Grant Record
External competitive grants as Principal Investigator
  • Health and Medical Research Fund, Food and Health Bureau, The Government of the HKSAR, 2021 – Fragility fractures in type 2 diabetes as an emerging diabetic complication: epidemiology, burden and strategies of primary prevention (Ref: 20211971; HKD 678,248)
  • Health and Medical Research Fund, Food and Health Bureau, The Government of the HKSAR, 2020 – The effect of simvastatin on bone density in postmenopausal women with type 2 diabetes: a double-blind, randomized, active-comparator (ezetimibe) controlled clinical trial (Ref: 19200931; HKD 1,478,393)


Key Office
  • Council member, Diabetes Division of Hong Kong Society of Endocrinology, Metabolism and Reproduction